These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25392115)

  • 41. Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?
    Charles B; Hardy J; Anderson H; Tapuni A; George R; Norris R
    Support Care Cancer; 2014 Feb; 22(2):325-30. PubMed ID: 24077699
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain.
    Hao GT; Zhou HY; Gao HZ; Qu HY; Liang YG; Li YY; Dong RH; Zhang LJ; Wang XF; Liu ZY
    Pharmacol Rep; 2014 Feb; 66(1):153-8. PubMed ID: 24905321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial.
    Narabayashi M; Saijo Y; Takenoshita S; Chida M; Shimoyama N; Miura T; Tani K; Nishimura K; Onozawa Y; Hosokawa T; Kamoto T; Tsushima T;
    Jpn J Clin Oncol; 2008 Apr; 38(4):296-304. PubMed ID: 18326541
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
    Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
    J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.
    Leuppi-Taegtmeyer A; Duthaler U; Hammann F; Schmid Y; Dickenmann M; Amico P; Jehle AW; Kalbermatter S; Lenherr C; Meyer Zu Schwabedissen HE; Haschke M; Liechti ME; Krähenbühl S
    Nephrol Dial Transplant; 2019 Apr; 34(4):692-702. PubMed ID: 30189012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy.
    Kokki M; Välitalo P; Rasanen I; Aaltomaa S; Ojanperä I; Eskelinen M; Kokki H
    Eur J Clin Pharmacol; 2012 Oct; 68(10):1357-63. PubMed ID: 22451244
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
    Chan S; Edwards SR; Wyse BD; Smith MT
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A transit compartment model unmasks OxyContin's reflective pharmacokinetics from urine measurements in humans.
    Linares OA; Schiesser WE; Linares AD; Stefanovski D; Boston RC
    J Pain Palliat Care Pharmacother; 2014 Jun; 28(2):96-108. PubMed ID: 24813654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Voriconazole drastically increases exposure to oral oxycodone.
    Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.
    Andreassen TN; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
    Eur J Clin Pharmacol; 2011 May; 67(5):493-506. PubMed ID: 21140139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets.
    Kim JY; Lee SH; Park CW; Rhee YS; Kim DW; Park J; Lee M; Seo JW; Park ES
    Drug Des Devel Ther; 2015; 9():695-706. PubMed ID: 25678774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Controlled-Release Oxycodone as "Gold Standard" for Postoperative Pain Therapy in Patients Undergoing Video-Assisted Thoracic Surgery or Thoracoscopy: A Retrospective Evaluation of 788 Cases.
    Kampe S; Weinreich G; Darr C; Stamatis G; Hachenberg T
    Thorac Cardiovasc Surg; 2015 Sep; 63(6):510-3. PubMed ID: 25602848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).
    Malhotra BK; Matschke K; Wang Q; Bramson C; Salageanu J
    Clin Drug Investig; 2015 Apr; 35(4):267-74. PubMed ID: 25724154
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an established oxycodone twice daily prolonged release tablet.
    Lux EA; Janecki M; Maritz MA
    Curr Med Res Opin; 2014 Nov; 30(11):2365-75. PubMed ID: 25050592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
    Lalovic B; Kharasch E; Hoffer C; Risler L; Liu-Chen LY; Shen DD
    Clin Pharmacol Ther; 2006 May; 79(5):461-79. PubMed ID: 16678548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
    J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone.
    Benziger DP; Miotto J; Grandy RP; Thomas GB; Swanton RE; Fitzmartin RD
    J Pain Symptom Manage; 1997 Feb; 13(2):75-82. PubMed ID: 9095564
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Central nervous system penetration of oxycodone after intravenous and epidural administration.
    Kokki M; Välitalo P; Kuusisto M; Ranta VP; Raatikainen K; Hautajärvi H; Kokki H
    Br J Anaesth; 2014 Jan; 112(1):133-40. PubMed ID: 24131664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets.
    Koizumi W; Toma H; Watanabe K; Katayama K; Kawahara M; Matsui K; Takiuchi H; Yoshino K; Araki N; Kodama K; Kimura H; Kono I; Hasegawa H; Hatanaka K; Hiraga K; Takeda F
    Jpn J Clin Oncol; 2004 Oct; 34(10):608-14. PubMed ID: 15591459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.